4BASEBIO UK SOCIETAS (4BB) - Net Assets
Based on the latest financial reports, 4BASEBIO UK SOCIETAS (4BB) has net assets worth GBX18.98 Million GBX (≈ $2.31K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX36.87 Million ≈ $4.49K USD) and total liabilities (GBX17.89 Million ≈ $2.18K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4BB asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX18.98 Million |
| % of Total Assets | 51.49% |
| Annual Growth Rate | N/A |
| 5-Year Change | 70.66% |
| 10-Year Change | N/A |
| Growth Volatility | 35.95 |
4BASEBIO UK SOCIETAS - Net Assets Trend (2019–2024)
This chart illustrates how 4BASEBIO UK SOCIETAS's net assets have evolved over time, based on quarterly financial data. Also explore total assets of 4BASEBIO UK SOCIETAS for the complete picture of this company's asset base.
Annual Net Assets for 4BASEBIO UK SOCIETAS (2019–2024)
The table below shows the annual net assets of 4BASEBIO UK SOCIETAS from 2019 to 2024. For live valuation and market cap data, see 4BASEBIO UK SOCIETAS market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX26.38 Million ≈ $3.21K |
+5461.79% |
| 2023-12-31 | GBX-492.00K ≈ $-59.86 |
-106.91% |
| 2022-12-31 | GBX7.12 Million ≈ $866.30 |
-39.12% |
| 2021-12-31 | GBX11.70 Million ≈ $1.42K |
-24.34% |
| 2020-12-31 | GBX15.46 Million ≈ $1.88K |
+917.88% |
| 2019-12-31 | GBX-1.89 Million ≈ $-229.96 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to 4BASEBIO UK SOCIETAS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2910200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX13.77 Million | 52.21% |
| Other Comprehensive Income | GBX14.08 Million | 53.38% |
| Other Components | GBX37.25 Million | 141.21% |
| Total Equity | GBX26.38 Million | 100.00% |
4BASEBIO UK SOCIETAS Competitors by Market Cap
The table below lists competitors of 4BASEBIO UK SOCIETAS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
iPower Inc
NASDAQ:IPW
|
$953.42K |
|
SDI Group plc
LSE:SDI
|
$954.26K |
|
Gemfields Plc
LSE:GEM
|
$954.54K |
|
Tangiamo Touch Technology AB
ST:TANGI
|
$956.09K |
|
Quhuo Ltd
NASDAQ:QH
|
$950.17K |
|
Fort St James Nickel Corp
V:FTJ
|
$949.38K |
|
Transforma Resources Corp
V:TFM
|
$947.04K |
|
Severfield PLC
LSE:SFR
|
$946.68K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 4BASEBIO UK SOCIETAS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -492,000 to 26,380,000, a change of 26,872,000.
- Net loss of 12,333,000 reduced equity.
- New share issuances of 39,184,000 increased equity.
- Other comprehensive income increased equity by 708,999.
- Other factors decreased equity by 687,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-12.33 Million | -46.75% |
| Share Issuances | GBX39.18 Million | +148.54% |
| Other Comprehensive Income | GBX709.00K | +2.69% |
| Other Changes | GBX-688.00K | -2.61% |
| Total Change | GBX- | % |
Book Value vs Market Value Analysis
This analysis compares 4BASEBIO UK SOCIETAS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 251.09x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | GBX-0.15 | GBX505.00 | x |
| 2020-12-31 | GBX1.25 | GBX505.00 | x |
| 2021-12-31 | GBX0.95 | GBX505.00 | x |
| 2022-12-31 | GBX0.58 | GBX505.00 | x |
| 2023-12-31 | GBX-0.04 | GBX505.00 | x |
| 2024-12-31 | GBX2.01 | GBX505.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 4BASEBIO UK SOCIETAS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1321.86%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.70x
- Recent ROE (-46.75%) is below the historical average (-25.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -209.41% | 0.17x | 0.00x | GBX-234.00K |
| 2020 | -4.65% | -155.63% | 0.03x | 1.15x | GBX-2.26 Million |
| 2021 | -27.66% | -957.10% | 0.02x | 1.26x | GBX-4.40 Million |
| 2022 | -72.33% | -1921.64% | 0.02x | 1.64x | GBX-5.86 Million |
| 2023 | 0.00% | -1514.82% | 0.04x | 0.00x | GBX-7.62 Million |
| 2024 | -46.75% | -1321.86% | 0.02x | 1.70x | GBX-14.97 Million |
Industry Comparison
This section compares 4BASEBIO UK SOCIETAS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $9,058,609
- Average return on equity (ROE) among peers: -271.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 4BASEBIO UK SOCIETAS (4BB) | GBX18.98 Million | 0.00% | 0.94x | $951.45K |
| Aptamer Group PLC (APTA) | $245.81K | -274.50% | 4.65x | $205.09K |
| Arecor Therapeutics PLC (AREC) | $5.35 Million | -191.36% | 0.63x | $303.20K |
| Avacta Group PLC (AVCT) | $29.89 Million | -21.30% | 0.06x | $3.99 Million |
| BSF Enterprise Plc (BSFA) | $3.58 Million | -25.96% | 0.13x | $27.33K |
| Bioventix (BVXP) | $11.01 Million | 51.43% | 0.08x | $1.10 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $32.00K | -956.25% | 1.81x | $127.81K |
| Amur Minerals Corporation (CRTX) | $20.48 Million | -8.91% | 0.04x | $80.26K |
| Fusion Antibodies PLC (FAB) | $50.13K | -935.06% | 5.06x | $193.60K |
| Faron Pharmaceuticals Oy (FARN) | $10.88 Million | -85.40% | 0.59x | $575.13K |
About 4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5' and 3' ends for viral and non-viral vector applicat… Read more